SCHEMBL6824367

SCHEMBL6824367

Cc1[nH]c2ccc(C(F)(F)F)cc2c1C1=NCCN1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 8/20 0.51
KIF11 P52732 4/20 0.48
CHUK O15111 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ADRA1A P35348 3/20 0.41
HTR1D P28221 1/20 0.41
ADRA2A P08913 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1B P35368 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7736130 0.99 NISCH (0.50) NISCHKIF11CHUKMEN1KMT2A
SCHEMBL6823738 0.90 NISCH (0.43) NISCHKIF11CHUKMEN1KMT2A
Hydrochloric Acid SCHEMBL7735219 0.89 NISCH (0.56) NISCHKIF11ADRA1AHTR1D
Hydrochloric Acid SCHEMBL6824121 0.89 NISCH (0.42) NISCHKIF11CHUKMEN1KMT2A
Hydrochloric Acid SCHEMBL7736764 0.86 NISCH (0.46) NISCHADRA1AHTR1D
Hydrochloric Acid SCHEMBL7736302 0.86 NISCH (0.48) NISCHADRA1AHTR1D
SCHEMBL6820796 0.85 NISCH (0.52) NISCHKIF11CHUKMEN1KMT2A
SCHEMBL6824373 0.82 NISCH (0.55) NISCHKIF11CHUK
SCHEMBL6824236 0.82 NISCH (0.50) NISCHMEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL7736313 0.81 NISCH (0.54) NISCHKIF11CHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R NISCH 277/4885KIF11 3145/4885CHUK 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.